SEC Filings

SEC Filings
Home / SEC Filings

SEC Filings

Form 8-K
PROTALIX BIOTHERAPEUTICS, INC. filed this Form 8-K on 07/25/2017
Document Outline
Entire Document (851.8 KB)
Subdocument 1 - 8-K - FORM 8-K
Page 1 - UNITED STATES
Page 2 - Item 1.01. Entry into a Material Definitive Agreement
Page 3 - Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arr
Page 4 - SIGNATURES
Subdocument 2 - EX-4.1 - EXHIBIT 4.1
Page 1 - Exhibit 4.1
Page 2 - Table of Contents
Page 3 - Table of Contents
Page 4 - Table of Contents
Page 5 - Table of Contents
Page 6 - Company
Page 7 - Agent
Page 8 - Cash Settlement
Page 9 - Clause A Distribution
Page 10 - Conversion Price
Page 11 - Default
Page 12 - Fundamental Change Purchase Date
Page 13 - Make-Whole Premium
Page 14 - Outstanding
Page 15 - Redemption Date
Page 16 - Share Make-Whole Premium Number
Page 17 - Transfer Agent
Page 18 - Acts of Holders
Page 19 - provided
Page 20 - Ranking
Page 21 - Registration; Registration of Transfer and Exchange
Page 22 - Agent Members
Page 23 - Persons Deemed Owners
Page 24 - In General; Transfer and Exchange of Beneficial Interests in Global Notes.
Page 25 - Transfer and Exchange of Physical Notes
Page 26 - Purchase of Notes; Cancellation
Page 27 - Payment and Computation of Interest
Page 28 - Purchase at Option of Holders upon a Fundamental Change
Page 29 - Fundamental Change Company Notice
Page 30 - provided
Page 31 - Deposit of Fundamental Change Purchase Price
Page 32 - Conversion Privilege
Page 33 - N/A
Page 34 - Conversion Date
Page 35 - provided
Page 36 - Make-Whole Premium upon Conversion.
Page 37 - N/A
Page 38 - Increased Conversion Rate Applicable to Certain Notes Surrendered in Connection with Make-Whole Adju
Page 39 - N/A
Page 40 - Adjustment of Conversion Rate
Page 41 - N/A
Page 42 - N/A
Page 43 - Spin-Off
Page 44 - Trigger Event
Page 45 - Clause C Distribution
Page 46 - Tender/Exchange Offer Valuation Period
Page 47 - provided
Page 48 - N/A
Page 49 - Adjustments of Prices
Page 50 - Merger Event
Page 51 - Certain Covenants
Page 52 - Notice to Holders Prior to Certain Actions
Page 53 - Certain Limitations on Settlement
Page 54 - Payment of Principal and Interest and the Fundamental Change Purchase Price
Page 55 - Provisions as to Paying Agent
Page 56 - provided
Page 57 - Additional Interest Notice
Page 58 - Corporate Existence
Page 59 - provided
Page 60 - Acceleration, Rescission and Annulment
Page 61 - provided
Page 62 - Waiver of Past Defaults
Page 63 - Collection of Indebtedness; Suit for Enforcement by Trustee
Page 64 - Restoration of Rights and Remedies
Page 65 - Undertaking for Costs
Page 66 - Discharge of Liability on Notes
Page 67 - Reinstatement
Page 68 - Supplemental Indentures with Consent of Holders
Page 69 - Notice of Amendment or Supplement
Page 70 - Successor Corporation to Be Substituted
Page 71 - Redemption Rights
Page 72 - provided
Page 73 - Payment of Notes Called for Redemption
Page 74 - Duties and Responsibilities of Trustee
Page 75 - Rights of the Trustee
Page 76 - Trustee s Disclaimer
Page 77 - Monies to be Held in Trust
Page 78 - Officer s Certificate as Evidence
Page 79 - provided
Page 80 - Succession by Merger, Etc
Page 81 - Trustee s Application for Instructions from the Company
Page 82 - Calculations
Page 83 - No Recourse Against Others
Page 84 - Tax Information.
Page 85 - Submission to Jurisdiction
Page 86 - IN WITNESS WHEREOF
Subdocument 3 - EX-4.2 - EXHIBIT 4.2
Page 1 - Exhibit 4.2
Page 2 - First Supplemental Indenture
Page 3 - Designation and Principal Amount
Page 4 - Governing Law
Page 5 - N/A
Page 6 - N/A
Subdocument 4 - EX-4.4 - EXHIBIT 4.4
Page 1 - Exhibit 4.4
Page 2 - Company
Page 3 - Notes
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - Company
Page 9 - N/A
Page 10 - Date
Subdocument 5 - EX-10.1 - EXHIBIT 10.1
Page 1 - Exhibit 10.1
Page 2 - Signature Page Follows
Page 3 - N/A
Page 4 - ANNEX A
Page 5 - Section 1.2
Page 6 - Annex C-2
Page 7 - Commission
Page 8 - Material Adverse Effect
Page 9 - Company Stock Option
Page 10 - N/A
Page 11 - N/A
Page 12 - Licenses
Page 13 - Health Care Laws
Page 14 - ERISA
Page 15 - FCPA
Page 16 - Intellectual Property
Page 17 - Successor Purchaser
Page 18 - Source of Funds
Page 19 - Legend
Page 20 - Covenants
Page 21 - Indemnification.
Page 22 - N/A
Page 23 - The provisions of this Section 5 will survive the Closing.
Page 24 - Survival of Agreements; Non-Survival of Company Representations and Warranties
Page 25 - Entire Agreement
Subdocument 6 - EX-10.2 - EXHIBIT 10.2
Page 1 - Exhibit 10.2
Page 2 - Agreement
Page 3 - Exchange Procedures
Page 4 - Authorization and Enforceability
Page 5 - Non-Contravention/No Consents
Page 6 - No Brokers
Page 7 - REPRESENTATIONS AND WARRANTIES OF THE PURCHASERS
Page 8 - No Brokers
Page 9 - No Encumbrances
Page 10 - Exhibit D
Page 11 - MISCELLANEOUS
Page 12 - apinedo@mofo.com
Page 13 - Governing Law
Page 14 - Withholding
Page 15 - IN WITNESS WHEREOF
Subdocument 7 - EX-99.1 - EXHIBIT 99.1
Page 1 - Exhibit 99.1
Page 2 - Forward-Looking Statements